Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
High Conviction Trades
Discover high conviction trades that caused a significant change in a fund's stake in a stock
Fund Manager Portfolios
Gain insights from the world’s largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Search
Sign in
Sign up
Novo Nordisk
NVO
Market cap
$169B
Overview
Fund Trends
Analyst Outlook
Journalist POV
37.96
USD
-0.06
0.16%
At close
Updated
Mar 13, 4:00 PM EDT
Pre-market
After hours
37.93
-0.03
0.08%
1D
5D
1M
3M
6M
YTD
1Y
5Y
10Y
1 day
-0.16%
5 days
-3.14%
1 month
-23.42%
3 months
-24.64%
6 months
-31.75%
Year to date
-27.54%
1 year
-49.98%
5 years
5.3%
10 years
32.59%
Upgrade to unlock
Positive
Neutral
Negative
Sentiment
3-Months
Positive
Neutral
26.3%
Negative
Positive
Neutral
Negative
Positive
The Motley Fool
yesterday
3 Dirt-Cheap Stocks to Buy With $1,000 Right Now
Investors are understandably fearful that Uber Technologies' profits are going to be under a growing degree of pressure. Insurer Progressive's outstanding 2025 results were too good to last.
Positive
Seeking Alpha
yesterday
Royce Smaller-Companies Growth Fund FY 2025: What Worked
Nine of the portfolio's 10 equity sectors made a positive impact on performance, with Health Care, Industrials, and Materials making the largest positive contributions. Palvella's shares appreciated significantly in 2025 as investors grew more confident in the company's pipeline following a grant from the FDA, patent wins, and a positive Phase II readout. Impinj is a long time holding in the portfolio with a very large total addressable market expansion opportunity, a strong patent portfolio, and an increasingly diversified customer base.
Neutral
Zacks Investment Research
2 days ago
Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Novo Nordisk (NVO) closed the most recent trading day at $38.02, moving 2.09% from the previous trading session.
Positive
Seeking Alpha
2 days ago
14 Ideal 'Safer' Dividend Buys From 70 Mid-March Graham Value All-Stars (GVAS)
Top ten large cap value (GASV) stocks are forecasted to deliver an average 38.12% net gain by mid-March 2027, with yields up to 13.03%. Analyst targets suggest the five lowest-priced, highest-yield GASV stocks could outperform, offering an 18.5% higher gain than the top ten as a group. Fourteen of twenty-nine 'safer' lowest-priced GASV stocks are currently buyable, with seven meeting the ideal dividend-to-price criteria for fair value.
Positive
Seeking Alpha
2 days ago
Hims & Hers Health And Novo Nordisk: A Corporate Remarriage That May Work Out Profitably
Hims & Hers Health (HIMS) is rated a Speculative Buy after its renewed partnership with Novo Nordisk, providing legitimate access to lucrative branded GLP-1 therapies. HIMS has demonstrated rapid revenue growth and improving profitability, with gross margins rising from 30% to nearly 75% and operating income turning positive. Valuation appears reasonable given future earnings growth potential, though current multiples are above sector averages on earnings but below on sales.
Negative
The Motley Fool
2 days ago
Does This Deal Make Novo Nordisk Stock a Buy?
Novo Nordisk will partner with Hims & Hers to sell affordable branded semaglutide. This will decrease competition from compounded versions of the drug.
Neutral
PRNewsWire
2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
GlobeNewsWire
2 days ago
Novo Holdings announces 2025 Annual Results
Total Income and Investment Returns in 2025 were DKK 21 billion (€2.8 billion). For 2025, Total Income and Investment Returns consisted of Income from dividends from the Novo Group companies (DKK 15 billion or €2.0 billion) and Returns from the Investment Assets Portfolio 1 (DKK 5.8 billion or €0.8 billion).
Negative
Reuters
3 days ago
India warns drugmakers against direct or surrogate weight-loss drug and obesity ads
India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns that could act as surrogate promotions, as global and domestic drugmakers seek a share of the country's fast-growing obesity drug market.
Positive
Seeking Alpha
3 days ago
This Novo Nordisk Partnership Shows That HIMS Has All The Leverage
Hims & Hers (HIMS) is still a Strong Buy, given that the transformative partnership with Novo Nordisk resolves legal risks and unlocks new growth avenues. HIMS' core value lies in its 2.5M+ cash-pay customer base, enabling leverage with major pharma and supporting expansion into branded drug programs. With the Novo deal, I anticipate 2026 revenue could exceed $3.1B, sustaining 20%+ annual growth through 2029 and materially improving EBITDA margins.
Show more
See News Rankings
Sign up
Sign in
Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
High Conviction Trades
Discover high conviction trades that caused a significant change in a fund's stake in a stock
Fund Manager Portfolios
Gain insights from the world’s largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Theme
Close